CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer – Poster Number: 1361
PYX-102, an Anti-KLRG1 Antibody, Enhances Cytotoxic Activity of CD8 T cells from PBMC and Human Tumor Samples by Blocking the Interaction Between KLRG1 and Cadherins Poster Number: 572
First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of anti Siglec-15 PYX-106 in Subjects with Advanced Solid Tumors Poster Number: 756
A First-in-Human Phase 1 Clinical Study Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of the EDB+FN targeting ADC PYX-201 in Participants with Advanced Solid Tumors Poster Number: 762
A Phase 2 Trial with a Safety Lead-in to Evaluate the Addition of Sotigalimab, a CD40 Agonistic Monoclonal Antibody, to Standard-of-Care Doxorubicin for the Treatment of Advanced Sarcoma
Tissue Assessment of Therapeutic Responses to Neoadjuvant SCRT with and without Anit-CD40 Immunotherapy Sotigalimab (Sotiga) in Rectal Cancer
Use of High-dimensional and Spatial Immune Profiling to Explore Sotigalimab (CD40 Agonist) Activation of Antigen Presenting Cells and T Cells in the Tumor Microenvironment in Patients with Esophageal/Gastroesophageal Junction Cancer
A Multicenter Phase 2 Study of Sotigalimab (CD40 Agonist) in Combination with Neoadjuvant Chemoradiation for Resectable Esophageal and Gastroesophageal Junction (GEJ) Cancers
Elucidating Factors of Therapeutic Response to Immunotherapy Combined with Neoadjuvant Radiation Therapy for Rectal Cancer
Multi-Omic Multi-Parameter Circulating Biomarker Analysis in Chemoimmunotherapy Combinations Identifies Unique Immune Activation Signatures in the Pancreatic Cancer Setting
